|Pazopanib versus sunitinib in metastatic renal-cell carcinoma|
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
|Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study|
B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ...
Journal of Clinical Oncology 32 (14), 1412-1418, 2014
|Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …|
T Powles, I Durán, MS Van Der Heijden, Y Loriot, NJ Vogelzang, ...
The Lancet 391 (10122), 748-757, 2018
|Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an …|
K Fizazi, S Tjulandin, R Salvioni, JR Germŕ-Lluch, J Bouzy, D Ragan, ...
Journal of clinical oncology 19 (10), 2647-2657, 2001
|Plasma AR and abiraterone-resistant prostate cancer|
A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ...
Science translational medicine 7 (312), 312re10-312re10, 2015
|Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer|
J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ...
Annals of Oncology 24 (4), 878-888, 2012
|Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial|
RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ...
The lancet oncology 15 (3), 286-296, 2014
|Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy|
International Prognostic Factors Study Group
Journal of Clinical Oncology 28 (33), 4906-4911, 2010
|Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment|
M Giuliano, A Giordano, S Jackson, KR Hess, U De Giorgi, M Mego, ...
Breast Cancer Research 13 (3), R67, 2011
|Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database|
A Lorch, C Bascoul-Mollevi, A Kramar, L Einhorn, A Necchi, C Massard, ...
J Clin Oncol 29 (16), 2178-84, 2011
|Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer|
U De Giorgi, V Valero, E Rohren, S Dawood, NT Ueno, MC Miller, ...
J Clin Oncol 27 (20), 3303-3311, 2009
|Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1.|
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
|Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal …|
BJ Escudier, C Porta, P Bono, U De Giorgi, O Parikh, RE Hawkins, ...
Journal of Clinical Oncology 30 (18_suppl), CRA4502-CRA4502, 2012
|Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial|
R Motzer, TE Hutson, J Reeves, R Hawkins, J Guo, P Nathan, M Staehler, ...
Ann Oncol 23 (Suppl. 9), ixe13, 2012
|Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution …|
V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ...
Annals of Oncology 28 (7), 1508-1516, 2017
|Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with …|
S Salvi, V Casadio, V Conteduca, SL Burgio, C Menna, E Bianchi, L Rossi, ...
British journal of cancer 112 (10), 1717, 2015
|Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells|
M Mego, U De Giorgi, S Dawood, X Wang, V Valero, E Andreopoulou, ...
International journal of cancer 129 (2), 417-423, 2011
|Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination|
M Giuliano, A Giordano, S Jackson, U De Giorgi, M Mego, EN Cohen, ...
Breast Cancer Research 16 (5), 440, 2014
|Germ cell tumours of the testis|
S Gori, S Porrozzi, F Roila, G Gatta, U De Giorgi, M Marangolo
Critical reviews in oncology/hematology 53 (2), 141-164, 2005
|Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors|
U De Giorgi, C Aliberti, G Benea, M Conti, M Marangolo
Clinical cancer research 11 (17), 6171-6176, 2005